POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.202
https://www.valueinhealthjournal.com/article/S1098-3015(21)01997-5/fulltext
Title :
POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01997-5&doi=10.1016/j.jval.2021.11.202
First page :
Section Title :
Open access? :
No
Section Order :
10975